We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia (THALI-HHT)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01485224
First Posted: December 5, 2011
Last Update Posted: August 29, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Carlo Balduini, IRCCS Policlinico S. Matteo
November 28, 2011
December 5, 2011
August 29, 2017
November 2011
October 2014   (Final data collection date for primary outcome measure)
Percentage of patients showing a decrease in the frequency, intensity and duration of epistaxis and in the blood transfusion requirement. [ Time Frame: up to 24 weeks ]
Cessation of nose bleeding will be defined as complete response. Reduction in the severity of any bleeding parameter less than complete response will represent partial response.
Same as current
Complete list of historical versions of study NCT01485224 on ClinicalTrials.gov Archive Site
  • Size and number of telangiectasias evaluated by endoscopy of nasal mucosa (recording images of the size and localization of telangiectasias) [ Time Frame: up to 24 weeks ]
  • Minimum dose of the drug that reduces bleeding [ Time Frame: up to 24 weeks ]
  • Time to response [ Time Frame: up to 24 weeks ]
  • Time to relapse after the end of treatment [ Time Frame: up to 24 weeks after the end of treatment ]
  • Number of adverse events [ Time Frame: up to 1 year ]
  • Correlations between biological parameters, response to treatment and side effects profile [ Time Frame: up to 24 weeks ]
    • Correlations between the mutations that are responsible for HHT and response to treatment
    • Correlations between polymorphisms of CYP2C19 and response to treatment
    • Correlations between polymorphisms of CYP2C19 and side effects profile
Same as current
Not Provided
Not Provided
 
Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia
Efficacy of Thalidomide in the Treatment of Severe Recurrent Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary hemorrhagic telangiectasia (HHT) (OMIM 187300 and 600376), also known as Rendu-Osler-Weber syndrome, is an autosomal dominant disease and has a prevalence between 1:5000 and 1:8000 in different populations. Clinically, the occurrence of mucocutaneous and gastrointestinal telangiectasias and of systemic arteriovenous malformations is commonly observed. Recurrent and severe epistaxis, due to the presence of telangiectasias in nasal mucosa, is the most common presentation of HHT, frequently leading to severe anemia requiring intravenous iron and blood transfusions. Although not life threatening, severe epistaxis has a great impact on quality of life in HHT patients and it represents the most important impediment in daily activities, that poses therapeutic challenge. Recently, angiogenesis has been implicated in the pathogenesis of HHT. Circulating concentrations of both TGF-beta and vascular endothelial growth factor (VEGF) are significantly elevated and therefore, anti-angiogenic substances may be effective in the treatment of vascular malformations in this disease. Thalidomide functions as a potent immunosuppressive and antiangiogenic agent. The aim of this study is to assess the clinical effects of thalidomide therapy on the severity of epistaxis in subjects with HHT who are refractory to standard therapies.

In the management of HHT epistaxis, multiple approaches have been tried, including electrocautery, laser, embolization, arterial ligation, but all approaches are largely palliative with variable results, many requiring repeated interventions. Except for nasal closure, surgical options offer, at best, limited hemorrhage-free intervals, but no definitive results and all have side effects. Moreover, currently, there is no established medical treatment available for these patients. To limit blood loss, the few medical treatments used include manipulation of the coagulation and fibrinolytic pathways or topical applications of anti-inflammatory drugs. However, multiple lesions disseminated over the entire mucosal surface are common in affected individuals, making local treatment difficult. Re-bleeding consumes a disproportionate share of healthcare resources devoted to multiple admissions, repeated endoscopies and blood transfusions.

Recently, angiogenesis has been implicated in the pathogenesis of HHT. Circulating concentrations of both TGF-beta and vascular endothelial growth factor (VEGF) are significantly elevated and therefore, anti-angiogenic substances may be effective in the treatment of vascular malformations in this disease.

Thalidomide functions as a potent immunosuppressive and antiangiogenic agent by inhibiting the phagocytic ability of inflammatory cells and the production of cytokines, such as tumor necrosis factor-alpha (TNF-a). It has been shown to be effective in the treatment of inflammatory diseases, in conditions associated with human immunodeficiency virus (HIV) infection, and in various cancers. Bleeding inhibition has been observed in HHT patients who received thalidomide as an antiangiogenic cancer therapy. A recent paper has reported that thalidomide treatment induced vessel maturation in an experimental model of HHT and reduced severe nosebleeds in six of the seven HHT patients studied. On the other hand, spectacular improvements have been described in patients with intestinal angiodysplasias, treated with thalidomide. In isolated case reports, patients with severe recurrent intestinal bleeding refractory to standard treatment achieved prolonged complete remission with thalidomide at a dose of 100 to 300 mg/day for a few months and tolerance was good. Cessation of bleeding was associated with a reduction in serum VEGF levels. These observations suggest that thalidomide might be useful for treatment of HHT patients and address significant unmet medical needs. Unfortunately, this drug exposes patients to the risk of severe side effects.

Drug metabolism is under control of a number of enzymes specific for each drug; among these enzymes, many show variable levels of activity and we can thus recognize in the population extensive (high or fast) metabolizers (EM) intermediate (IM) and poor (low or slow) metabolizers (PM). This is true also for thalidomide, whose metabolism is in part controlled by the enzyme CYP2C19.

The aims of our study are to test the hypothesis that thalidomide reduces the bleeding tendency of HHT patients and to verify to which extent CYP2C19 polymorphism modulates both response to treatment and side effects.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Hereditary Hemorrhagic Telangiectasia
  • Epistaxis
Drug: Thalidomide

Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.

Treatment will be continued until one of the following criteria is met:

  • 8 additional weeks of treatment after the achievement of complete response
  • 16 additional weeks of treatment after the achievement of partial response
  • 24 weeks of treatment completed without response
  • unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks.
Other Name: Thalidomide Celgene
Experimental: Thalidomide

Single arm study:

Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.

Treatment will be continued until one of the following criteria is met:

  • 8 additional weeks of treatment after the achievement of complete response
  • 16 additional weeks of treatment after the achievement of partial response
  • 24 weeks of treatment completed without response
  • unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks.
Intervention: Drug: Thalidomide

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
31
October 11, 2016
October 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of HHT, according to the diagnostic criteria world-wide recognized (Curacao criteria), with severe recurrent epistaxis (grade 2-3 according to the criteria proposed by Pagella et al., i.e. at least one episode of overt bleeding/week requiring at least one blood transfusion during the last three months), and refractory to mini-invasive surgical procedures, i.e. argon plasma coagulation. For these patients, there is no effective treatment option currently available
  • Age > 18 years
  • Ability of signing written informed consent
  • Women of childbearing potential:
  • declared intention not to start a pregnancy throughout the study and for four weeks following the date of the last dose of thalidomide (safe contraception, see Celgene guidelines, "Programma di Prevenzione della Gravidanza")
  • negative serum pregnancy test obtained within 48 hours prior to the first dose of Thalidomide
  • declared intention to undergo pregnancy tests periodically while on the study medication
  • Males with female partner of childbearing potential:
  • declared intention not to father throughout the study and for one week following the date of the last dose of thalidomide (safe contraception, see Celgene guidelines, "Programma di Prevenzione della Gravidanza")
  • Estimated life expectancy must be greater than 10 months

Exclusion Criteria:

  • Pregnant or lactating women, or potentially fertile (both males and females) who have not agreed to avoid pregnancy during the trial period and for four weeks (females) or one week (males) following the date of the last dose of thalidomide
  • Neurological diseases
  • Psychiatric illness that would prevent granting of informed consent
  • Active cardiovascular disease
  • High risk for thromboembolic events (comorbidities, such as diabetes or uncontrolled infections, malignancy, immobility, prior history of thromboembolic events, use of erythropoietic agents or other agents such as hormone replacement therapy, central venous catheter, anti-cardiolipin, or anti-beta2 glycoprotein antibodies)
  • Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption since thalidomide capsules contain lactose
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01485224
EudratCT 2011-004096-36
Yes
Not Provided
Plan to Share IPD: No
Carlo Balduini, IRCCS Policlinico S. Matteo
IRCCS Policlinico S. Matteo
Not Provided
Principal Investigator: Carlo Balduini, M.D. Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
IRCCS Policlinico S. Matteo
August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP